More than one in six men will develop prostate cancer in their lifetime. In recent years there has been an explosion of information regarding PSA screening and biomarkers for the disease. In Prostate Cancer Screening, Second Edition, the world’s leading experts on prostate cancer detection update the first edition with the latest findings. The book incorporates a series of thoughtful and cutting-edge works from the world’s experts in prostate cancer screening, ranging from the current status quo of prostate cancer screening across the globe to consensus on optimal utilization of the traditional PSA and DRE tests, to cutting-edge research in new biomarkers, biomeasures, and extended risk algorithms for prostate cancer. An additional chapter covers family-based linkage analysis as well as possible pitfalls in prostate cancer biomarker evaluation studies. Timely and authoritative, Prostate Cancer Screening, Second Edition, is an essential text for urologists, oncologists and family physicians, as well as researchers in the biomarker industry who seek methods to better develop and support markers and measures of prostate cancer.
With one man in six expected to develop prostate cancer during his lifetime, and with a variety of risk factors often complicating clinical assessment and treatment planning, the question of whether, and when, prostate screening should be performed has become the subject of heated debate. In Prostate Cancer Screening, world-class authorities from a variety of disciplines provide a comprehensive and balanced evaluation of the advantages and disadvantages of screening for prostate cancer. These experts critically review the various methods by which screening can be performed, evaluate the screening itself, compare prostate screening with screening at other organ sites, and explore the impact of screening on a multitude of other medical and social issues. In addition, the book includes a CD-ROM containing a sophisticated-but simple to use-decision-making program that allows the physician to gage a patient's risk of prostate cancer. Called CAPRI (Cancer of the Prostate Risk Index), this PC-based program uses the four most significant factors-a patient's PSA value, the results of the digital rectal exam, the patient's race, and the patient's age at biopsy-to predict the risk of prostate cancer. The patient's risk (with confidence intervals if desired) is displayed in an easily understood, visually provocative manner that allows both clinician and patient to more easily reach the decision as to whether biopsy is appropriate, as well as to educate the patient in general.
Comprehensive and balanced, Prostate Cancer Screening, presents a lively and rigorous evaluation of the science of prostate cancer screening, affording the health care provider with an informative discussion of its pros and cons, together with user-friendly computer program that analyzes an individual patient's risk of prostate cancer.
